Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ramakrishna Battini (NPI 1710122601)

Field	Value
Entity Type	Individual
Organization	Ramakrishna Battini
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 8, 2008

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: lifetime Medicare revenue is $3.3M while Medicaid shows none (no Medicaid billing on file). The absence of any Medicaid billing on file indicates the practice’s revenue and utilization profile are driven almost entirely by Medicare beneficiaries, which has implications for payer mix risk and contracting leverage with commercial and state payers.

Revenue is highly concentrated in a handful of oncology infusions: the precomputed top 3 Medicare codes account for 66.8% of total Medicare revenue. The top three drivers are J9271 ($1.2M revenue, 37.2% of this provider's total Medicare revenue), J9299 ($569.3K revenue, 18.1% of this provider's total Medicare revenue), and J9144 ($362.5K revenue, 11.5% of this provider's total Medicare revenue), indicating a practice built around high-cost monoclonal antibody and immunotherapy administration.

The code mix and descriptions point to an infusion‑centric hematology/oncology operation: dominant billing for J9271, J9299 and J9144 (pembrolizumab, nivolumab, and daratumumab products) together with chemotherapy administration codes such as 96413 and add‑on infusion codes like 96417 indicate routine outpatient infusion suites and ongoing cancer treatment management. Additional supportive medications and services (for example J2506 pegfilgrastim and M0010 enhanced oncology model payments) further support a care model focused on active oncology treatment and care coordination.

Competitive standing on key agents is solid but not monopolistic: J9271 ranks #171 of 1841 providers nationally (90th percentile; typical, unremarkable volume), J9299 ranks #117 of 505 providers (77th percentile; typical, unremarkable volume), and J9144 ranks #230 of 615 providers (61th percentile; typical, unremarkable volume). These rankings imply the provider is a meaningful national participant for these immunotherapies—above average in activity for some agents—but not a dominant outlier nationally.

There are selective high‑volume procedural signals and some statistical outliers among supportive-service codes: 96413 is described as notably above typical national volume (94th percentile), and 96367 also sits at the 94th percentile, which together suggest above‑average chemotherapy/infusion throughput relative to peers. High percentile lab test volumes (80048 at 97th percentile and 80076 at 94th percentile) indicate substantial onsite or ordered laboratory monitoring supporting active oncology care.

Usage of newer or biosimilar agents appears specialized: J9358 (fam‑trastuzumab deruxtecan) shows $150K revenue and an unusual national rank (#5 of 6 providers, 20th percentile; typical, unremarkable volume), suggesting this provider is among a very small set of billers for that code nationally. Similarly, some biosimilar entries (Q5123 rituximab‑arrx at $49K and rank #32 of 40, 18th percentile) point to selective adoption of biosimilars rather than broad high-volume biosimilar billing.

The provider has long tenure in the Medicare program, with NPI enumeration dated 2008-12-08 (~18 years ago), consistent with an established hematology/oncology practice likely to have an ongoing referral base and operational infrastructure for infusion services. Combined with the concentrated Medicare revenue and zero Medicaid billing, this tenure suggests stability in a Medicare‑focused oncology business model but limited exposure to Medicaid patient populations.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

94 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,200	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	23,720	$20	$569.3K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,540	$40	$362.5K
J9173	Injection, durvalumab, 10 mg	3,720	$60	$230.8K
J0897	Injection, denosumab, 1 mg	8,580	$20	$154.4K
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	7,500	$20	$150K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,000	$40	$70K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	2,980	$20	$68.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	570	$90	$52.1K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	1,400	$40	$49K

Showing 1–10 of 94

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 94 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Ramakrishna Battini — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

94 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	9	50	17,400	$40	$776.1K
J9299	6	20	21,010	$20	$487.5K
J9144	12	20	10,080	$40	$466.3K
J9173	3	10	3,720	$60	$211.7K
J1569	23	30	3,030	$40	$175.2K
J9358	3	10	7,850	$20	$156.7K
J0897	33	240	2,940	$20	$85K
Q5107	9	20	2,990	$20	$77.6K
Q5123	11	10	1,960	$40	$70.9K
J0881	32	70	19,050	$1	$54.4K

Showing 1–10 of 94

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ramakrishna Battini, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0
Sonia Benn	MS	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as Ramakrishna Battini, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Ramakrishna Battini — Billing Profile & Reimbursement Data

Sign up for Ramakrishna Battini — Billing Profile & Reimbursement Data policy alerts

Ramakrishna Battini — Billing Profile & Reimbursement Data

Sign up for Ramakrishna Battini — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References